When cancer is diagnosed, finding treatment options is the top priority
OncoTarget® Series is our comprehensive genomic profiling solution to identify targeted immunotherapies for advanced cancers– solid tumors or leukemias.
Learn about our newly launched, FDA cleared, 500-gene panel - OncoTarget® 500*
OncoTarget® Series Test Menu
OncoTarget® 500
FDA cleared gene panel testing

  • Cleared for all solid tumors
  • 100% clinical biomarkers covered
  • Includes: CDx, NCCN guideline-directed targeted genes
  • Cost-effective
  • Timely
OncoTarget® Liquid
Coming soon
OncoTarget® Myeloid68
An NGS-Based Test For Myeloid Leukemia

  • NGS-bases gene panel (68 genes)
  • High density coverage of sequencing reads
  • Targets known mutations associated with acute myeloid leukemia (AML), MPN, MDS, CML and JMML

Hematology Molecular Panel

AML Prognostics:
  • FLT3
  • NPM1
  • CEBPA
  • TP53
CML Residual Disease:
  • BCR-ABL1 Mbcr (p210) Quantitative Analysis for Minimal Residual Disease (MRD)
Myleoid NGS 68 Panel:
  • 68 Genes Targeted Whole Exon Sequencing
MPN Diagnostics:
  • JAK2 V617F:
  1. If Neg, Reflex to JAK2 Exon 12
  2. If Neg, Reflex to MPL
  3. If Neg, Reflex to CALR
  • CALR
  • JAK2 Exon 12
  • MPL
  • PDGFRA
  • TET2
Lymphocytic Leukemia/Lymphoma:
  • T-CELL Gene Rearrangement
  • B-CELL Gene Rearrangement

Hematology FISH Panel

Acute Lymphocytic Leukemia (ALL) panel:
  • t(1;19) PBX1/TCF3
  • t(9;22) BCR/ABL1
  • 11q23 KMT2A (MLL) rearrangements
  • t(12;21) ETV6(TEL)/RUNX1(AML)
  • trisomy 4, 5, 10, 17

Acute Myelogenous (AML) panel:
  • inv(3), t(3;3) RPN1/MECOM rearrangements
  • del(5q) EGR1
  • del(7q)/monosomy 7
  • t(8;21) RUNX1T1(ETO)/RUNX1(AML)
  • 11q23 KMT2A (MLL) rearrangements
  • t(15;17) PML/RARA
  • inv(16), t(16;16) CBFB rearrangements

Chronic Lymphocytic (CLL) panel:
  • del(11q) ATM/del(17p) TP53
  • trisomy 12/del(13q) 13q14/13q34
  • t(11;14) CCND1/IGH XT

Chronic Myelogenous (CML) probe:
  • t(9;22) BCR/ABL1

Myelodysplastic (MDS) panel:
  • inv(3), t(3;3) RPN1/MECOM rearrangements
  • del(5q) EGR1
  • del(7q)/monosomy 7
  • trisomy 8/del(20q)
  • 11q23 KMT2A (MLL) rearrangements
  • del(13q) 13q14/13q34

Multiple Myeloma (MM) panel:
  • 1p32.3/1q21 CDKN2C/CKS1B
  • t(11;14) CCND1/IGH XT
  • del(13q) 13q14/13q34
  • del(17p) TP53
  • reflex:
  1. t(4;14) FGFR3/IGH
  2. t(14;16) IGH/MAF
Myeloproliferative (MPN) panel:
  • del(5q) EGR1
  • del(7q)/monosomy 7
  • trisomy 8/del(20q)
  • t(9;22) BCR/ABL1
  • 11q23 KMT2A MLL rearrangements
  • 4q12 FIP1L1/CHIC2/PDGFRA
  • 5q33 PDGFRB rearrangements
  • 8p11 FGFR1 rearrangements
Non-Hodgkins Lymphoma (NHL) panel:
  • 2p23 ALK (Anaplastic) rearrangements
  • 3q27 BCL6 rearrangements (Diffuse Large B-cell, Follicular, Marginal Zone B-cell)
  • 8q24 MYC rearrangements
  • t(11;14) CCND1/IGH XT (Mantle Cell)
  • 18q21 BCL2 rearrangements
  • reflex:
  1. t(8;14) MYC/IGH (Burkitt or Follicular)
  2. t(11;18) BIRC3/MALT1
  3. t(14;18) IGH/BCL2
T-cell Leukemia/Lymphoma panel:
  • 2p23 ALK (Anaplastic) rearrangements
  • 14q11.2 TRA rearrangements
  • 7q34 TRB rearrangements
  • i(7q) 7cen/7q22/7q31
  • 14q32 TCL1A
  • 10q24 TLX1
  • 5q35 TLX3

Immuno Profile Panel

  • PDL-1
  • MSI
  • MMR
Your confidence is found within OncoTarget’s
multi-technology platform
MSI and Single Mutations
FISH
next-generation sequencing
Immunohistochemistry